Strengthening Airway Immunity Could Advance Respiratory Vaccines and Therapies
en-GBde-DEes-ESfr-FR

Strengthening Airway Immunity Could Advance Respiratory Vaccines and Therapies

17/11/2026 Compuscript Ltd


A review published in Genes & Diseases highlights how strengthening immunity in the nose and airways could improve protection against respiratory infections. Researchers at West China Hospital, Sichuan University, examine the respiratory mucosa as both a frontline defence system and a target for vaccines and inhalable antibody therapies.

The respiratory mucosa is the tissue lining the airways, where inhaled pathogens first encounter the body’s defences. Its protective network combines physical barriers, mucus clearance, antimicrobial molecules, and immune cells. Crucially, it must eliminate harmful invaders while tolerating harmless substances and avoiding inflammation that damages lung tissue.

The review explains five functions: immune tolerance, barrier protection, immune surveillance, tissue repair, and long-term immune memory. Disruption of these processes can contribute to viral, bacterial, and fungal infections, as well as chronic inflammatory conditions such as asthma and chronic obstructive pulmonary disease.

A central focus is vaccination at the respiratory portal of entry. Intranasal and inhaled approaches aim to build local protection alongside systemic immunity. Secretory immunoglobulin A, an antibody found at mucosal surfaces, and tissue-resident memory T cells are important components of this defence, helping recognise pathogens and respond where infection begins.

The article surveys live-attenuated, inactivated, viral vector, protein subunit, and mRNA vaccine platforms. It also considers delivery technologies and immune-enhancing strategies designed to help vaccine components reach tissues and produce longer-lasting responses.

In parallel, inhalable antibodies offer a potential route to rapid local protection or early treatment. Delivering antibodies directly to airway surfaces could concentrate antiviral activity at infection sites. However, the review notes that promising antiviral findings have not always translated into clinical improvements, and formulation stability remains challenging.

The researchers outline three priorities for future vaccine design: strengthen immunity in the upper airways, broaden antigen coverage beyond narrowly matched strains, and establish intranasal safety. These priorities could support more durable protection and preparedness for emerging respiratory pathogens.

Important barriers remain. Airway anatomy, mucus, airflow, and rapid clearance can make delivery inconsistent between individuals. Immune responses may also fade, while stronger immune stimulation can increase local inflammation. Reliable measures that predict mucosal protection are still needed.

The review emphasises that animal results do not guarantee effectiveness in humans. Better clinical studies, standardised sampling methods, and long-term monitoring will be essential to assess both protection and safety.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 |Impact Factor:14.6
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)
# # # # # #
Reference
Yu Zhang, Zhiruo Song, Weiqi Hong, Xuemei He, Xiawei Wei, Respiratory mucosal immunity: Biological functions, diseases, prevention and therapy, Genes & Diseases, Volume 13, Issue 6, 2026, 102200, https://doi.org/10.1016/j.gendis.2026.102200

Funding
National Key Research and Development Program of China 2024YFC2310700
1.3.5 project for disciplines of excellence from West China Hospital of Sichuan University (China) ZYGD23038
Project of the Science and Technology Department of Sichuan Province, China 2023NSFSC1655
National Natural Science Foundation of China Young Student Basic Research Program (China) 323B2050
China Postdoctoral Science Foundation (China) 2025M782195
Sichuan Science and Technology Program (China) 2026NSFSC1763
Yu Zhang, Zhiruo Song, Weiqi Hong, Xuemei He, Xiawei Wei, Respiratory mucosal immunity: Biological functions, diseases, prevention and therapy, Genes & Diseases, Volume 13, Issue 6, 2026, 102200, https://doi.org/10.1016/j.gendis.2026.102200
Fichiers joints
  • Image Caption: Adaptive immune responses in the RM immune system
  • Image Caption: Immune-programming features of respiratory mucosal vaccine platforms.
  • Image Caption: Antigen strategy upgrade roadmap for next-generation respiratory vaccines.
17/11/2026 Compuscript Ltd
Regions: Europe, Ireland, Asia, China
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Témoignages

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Nous travaillons en étroite collaboration avec...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by DNN Corp Terms Of Use Privacy Statement